PL3328864T3 - Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych - Google Patents
Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnychInfo
- Publication number
- PL3328864T3 PL3328864T3 PL16820570.6T PL16820570T PL3328864T3 PL 3328864 T3 PL3328864 T3 PL 3328864T3 PL 16820570 T PL16820570 T PL 16820570T PL 3328864 T3 PL3328864 T3 PL 3328864T3
- Authority
- PL
- Poland
- Prior art keywords
- disorders
- compositions
- therapeutic compounds
- substance use
- treating social
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015902659A AU2015902659A0 (en) | 2015-07-06 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| PCT/AU2016/050588 WO2017004674A1 (en) | 2015-07-06 | 2016-07-06 | Therapeutic compounds and compositions for treating social disorders and substance use disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3328864T3 true PL3328864T3 (pl) | 2023-02-27 |
Family
ID=57684596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16820570.6T PL3328864T3 (pl) | 2015-07-06 | 2016-07-06 | Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11033555B2 (pl) |
| EP (1) | EP3328864B1 (pl) |
| JP (2) | JP7089825B2 (pl) |
| KR (1) | KR102686349B1 (pl) |
| CN (1) | CN107922420B (pl) |
| AU (1) | AU2016289271B2 (pl) |
| DK (1) | DK3328864T3 (pl) |
| ES (1) | ES2932194T3 (pl) |
| HU (1) | HUE060496T2 (pl) |
| IL (1) | IL256684B (pl) |
| MX (1) | MX389545B (pl) |
| PL (1) | PL3328864T3 (pl) |
| PT (1) | PT3328864T (pl) |
| RU (1) | RU2715384C2 (pl) |
| SI (1) | SI3328864T1 (pl) |
| WO (1) | WO2017004674A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3328864T3 (pl) | 2015-07-06 | 2023-02-27 | Kinoxis Therapeutics Pty Ltd | Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych |
| CA3046809A1 (en) * | 2016-12-12 | 2018-06-21 | The University Of Sydney | Non-peptide oxytocin receptor agonists |
| US20220079953A1 (en) * | 2018-11-23 | 2022-03-17 | The University Of Sydney | Methods for management of weight |
| KR20220063198A (ko) * | 2019-09-06 | 2022-05-17 | 키녹시스 테라퓨틱스 피티와이 리미티드 | 아편유사제 금단의 치료 |
| US20240287074A1 (en) * | 2020-09-07 | 2024-08-29 | Kinoxis Therapeutics Pty Ltd | Salts and crystals |
| JP2023552485A (ja) * | 2020-12-14 | 2023-12-15 | キノシス・セラピューティクス・ピーティーワイ・リミテッド | オキシトシン受容体モジュレーター |
| AU2022240104A1 (en) * | 2021-03-18 | 2023-10-05 | Kinoxis Therapeutics Pty Ltd | Methods of treatment |
| CN115677585B (zh) * | 2022-10-31 | 2024-03-19 | 上海群力化工有限公司 | 一种甲醛吡唑衍生物的合成工艺 |
| EP4617260A1 (en) | 2022-11-09 | 2025-09-17 | Mitsubishi Gas Chemical Next Company, Inc. | Production method for 1-alkyl-5-hydroxypyrazole |
| WO2025172368A1 (en) | 2024-02-13 | 2025-08-21 | Syngenta Crop Protection Ag | (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025210095A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline compounds |
| WO2026022173A1 (en) | 2024-07-26 | 2026-01-29 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
| CN119386023A (zh) * | 2024-10-25 | 2025-02-07 | 南方医科大学南方医院 | 地尔硫卓在制备治疗自闭症的药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| EP1512687A1 (en) * | 2003-09-05 | 2005-03-09 | Ferring B.V. | Piperazines as oxytocin agonists |
| EP1632494A1 (en) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| AU2006306547A1 (en) | 2005-10-24 | 2007-05-03 | Wyeth | Tricyclic compounds useful as oxytocin receptor agonists |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| EP2571360A4 (en) | 2010-05-19 | 2013-07-31 | Univ North Carolina | METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS |
| GB201015371D0 (en) | 2010-09-14 | 2010-10-27 | Optinose As | Nasal delivery |
| KR20140124465A (ko) | 2013-04-17 | 2014-10-27 | 인제대학교 산학협력단 | 사회 정서 관련 행동 조절을 위한 비강용 옥시토신의 용도 |
| PL3328864T3 (pl) * | 2015-07-06 | 2023-02-27 | Kinoxis Therapeutics Pty Ltd | Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych |
| KR20220063198A (ko) | 2019-09-06 | 2022-05-17 | 키녹시스 테라퓨틱스 피티와이 리미티드 | 아편유사제 금단의 치료 |
| AU2022240104A1 (en) | 2021-03-18 | 2023-10-05 | Kinoxis Therapeutics Pty Ltd | Methods of treatment |
-
2016
- 2016-07-06 PL PL16820570.6T patent/PL3328864T3/pl unknown
- 2016-07-06 DK DK16820570.6T patent/DK3328864T3/da active
- 2016-07-06 JP JP2018500416A patent/JP7089825B2/ja active Active
- 2016-07-06 CN CN201680040337.2A patent/CN107922420B/zh active Active
- 2016-07-06 PT PT168205706T patent/PT3328864T/pt unknown
- 2016-07-06 KR KR1020187003161A patent/KR102686349B1/ko active Active
- 2016-07-06 RU RU2018103873A patent/RU2715384C2/ru active
- 2016-07-06 SI SI201631630T patent/SI3328864T1/sl unknown
- 2016-07-06 MX MX2017017171A patent/MX389545B/es unknown
- 2016-07-06 AU AU2016289271A patent/AU2016289271B2/en active Active
- 2016-07-06 ES ES16820570T patent/ES2932194T3/es active Active
- 2016-07-06 HU HUE16820570A patent/HUE060496T2/hu unknown
- 2016-07-06 EP EP16820570.6A patent/EP3328864B1/en active Active
- 2016-07-06 WO PCT/AU2016/050588 patent/WO2017004674A1/en not_active Ceased
- 2016-07-06 US US15/738,532 patent/US11033555B2/en active Active
-
2018
- 2018-01-01 IL IL256684A patent/IL256684B/en unknown
-
2021
- 2021-05-07 US US17/314,664 patent/US11890287B2/en active Active
-
2022
- 2022-06-07 JP JP2022092261A patent/JP7490018B2/ja active Active
-
2023
- 2023-12-19 US US18/544,956 patent/US12458648B2/en active Active
-
2025
- 2025-10-10 US US19/355,732 patent/US20260034142A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256684B (en) | Medicinal compounds and preparations for the treatment of social disorders and substance use disorders | |
| IL256166B (en) | Compounds for use in treating neuromuscular disorders | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| IL251066B (en) | Preparations and methods for the treatment of metabolic disorders | |
| ZA201700311B (en) | Compositions and methods of use for treating metabolic disorders | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| SG10202013034QA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SI3261726T1 (sl) | Sestavek za zdravljenje aken | |
| IL258032B (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| ZA201807653B (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| IL251616A0 (en) | Methods and compounds for the treatment and prevention of muscle loss | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| SG11201705524SA (en) | Compositions and methods for the treatment of inflammation and pain | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| IL249440B (en) | Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases | |
| SG11201802292UA (en) | Composition for treating pain | |
| PL3377089T3 (pl) | Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego | |
| GB201513543D0 (en) | Compositions for use in the treatment of diabetes | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| AU2015902659A0 (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes | |
| SG10201400824YA (en) | Therapeutic Methods And Compositions For Treating Diabetes Utilizing Diterpenoid Compounds | |
| PT3524255T (pt) | Composição para o tratamento do acne |